Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0843
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer ; volume:80 ; number:6 ; day:11 ; month:8 ; year:2017 ; pages:1063-1072 ; date:12.2017
Cancer chemotherapy and pharmacology ; 80, Heft 6 (11.8.2017), 1063-1072, 12.2017
- Keyword
-
Krebs
Onkologie
- Creator
-
Matsubara, Nobuaki
- Contributor
-
Mukai, Hirofumi
Hosono, Ako
Onomura, Mai
Sasaki, Masaoki
Yajima, Yoko
Hashizume, Kensei
Yasuda, Masanobu
Uemura, Miho
Zurth, Christian
SpringerLink (Online service)
- DOI
-
10.1007/s00280-017-3417-3
- URN
-
urn:nbn:de:1111-201801134222
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Matsubara, Nobuaki
- Mukai, Hirofumi
- Hosono, Ako
- Onomura, Mai
- Sasaki, Masaoki
- Yajima, Yoko
- Hashizume, Kensei
- Yasuda, Masanobu
- Uemura, Miho
- Zurth, Christian
- SpringerLink (Online service)
Other Objects (12)
An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Ureter metastatic castration-resistant prostate cancer: a case report
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI)
Analysis of regulation of angiogenesis by androgen receptor ligands in castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Ureter metastatic castration-resistant prostate cancer: a case report
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI)
Analysis of regulation of angiogenesis by androgen receptor ligands in castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Ureter metastatic castration-resistant prostate cancer: a case report
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI)
Analysis of regulation of angiogenesis by androgen receptor ligands in castration-resistant prostate cancer